Kidney International

Abstract Background. Tuberous Sclerosis Complex (TSC) is caused by inactivating mutations in either the TSC1 or TSC2 genes, leading to activation of the mammalian target of rapamycin complex 1 (mTORC1) and unhindered cell growth and proliferation. The epithelium of TSC renal cysts in both mice and humans is composed of proliferating A-intercalated (A-IC) cells. The exact molecular mechanism of kidney cystogenesis in TSC remains speculative. Hypothesis.Superfluous cell proliferation driven by mTORC1 activation increases metabolic demand, causing oxidative stress and excess reactive oxygen species. If unchecked, this overwhelms antioxidant defenses and causes cell death. In TSC kidney cystogenesis, Nuclear Factor Erythroid 2-Related Factor 2 (NFE2L2), also known as NRF2, serves as the "master regulator" of antioxidant and anti-inflammatory responses, enabling cells to survive and proliferate by clearing the toxic environment and supplying nutrients and fuel. Results. RNA-seq and proteomics, along with western blot analysis, showed robust downregulation of Fumarate Hydrase 1 (FH1) and upregulation of NRF2, STAT3, and HIF1 in kidneys from TSC mice with moderate or heavy cyst burden. Confocal microscopy and immunohistochemical staining on kidney sections, and/or western blot studies on nuclear and cytoplasmic fractions, showed nuclear localization of NRF2, STAT3, and HIF1. In cyst-lining cells in TSC mouse models, FH1 downregulation was associated with inactivating succination of KEAP1 in immunoprecipitation experiments, promoting NRF2 nuclear localization in A-IC cells lining the cysts. NRF2 nuclear localization was associated with ectopic induction of the glutamine transporter SLC38A3 (SNAT3) on the basolateral membrane and activation of the NH3/NH4+ transporters RHCG and RHBG in A-IC cells lining the cysts. Twenty-four h urine NH3/NH4+ excretion rates increased significantly in Tsc1 KO vs. WT mice. The activation of NRF2, STAT3, and HIF1 can drive metabolic reprogramming and activate survival genes in proliferating cells. Together with SLC38A3 induction and upregulation of other glutamine and NH3/NH4+ transporters, these factors activate glutaminolysis and aerobic glycolysis, supplying nutrients to proliferating cystic epithelial cells and supporting cyst expansion in TSC. Consistent with this central role for glutaminolysis in kidney cystic epithelium and TSC cystogenesis, we find a significant reduction in kidney cyst burden in Tsc1 KO mice on a glutamine-free diet. Conclusions. NRF2 plays a critical role in antioxidant defense. Along with STAT3 and HIF1, NRF2 is a key player in metabolic reprogramming through glutaminolysis, which supplies nutrients to proliferating cystic epithelial cells and supports cyst expansion in TSC. These findings suggest that inhibiting or inactivating NRF2, alone or in combination with HIF1 or STAT3, may represent a potential treatment strategy for kidney lesions in TSC.

Banff acute lesion scores underpin histologic classification of kidney allograft biopsies; however, biomarker studies rely on second-order associations with diagnostic categories that introduce confounding. We quantified the first-order relationships between Banff acute lesion scores and the validated urinary cell three-gene rejection signature. In 354 biopsy-urine pairs, three-gene signature scores computed using a locked regression equation incorporating absolute copy numbers of CD3E mRNA, CXCL10 mRNA, and 18S rRNA in urinary cell RNA-were related to glomerulitis (g), peritubular capillaritis (ptc), interstitial inflammation (i), and tubulitis (t). Signature scores rose monotonically with Banff acute lesion severity, with 1.5 to 1.8-fold higher odds of more severed g, ptc, i, and t (all P<0.0001), and showed good calibration. Associations remained robust for composite microvascular (g+ptc) and tubulointerstitial (i+t) indices and were strongest for severe g and t, supporting this signature as a noninvasive, quantitative readout of acute rejection pathology with immediate diagnostic applicability.

Background IgA vasculitis (IgAV) is the most common systemic vasculitis in children, and its prognosis is largely determined by renal involvement (IgAV nephritis). No routine blood test identifies IgAV or stratifies the risk of nephritis, although aberrant O-glycosylation of the IgA1 hinge region is central to its pathogenesis. We developed a mass-spectrometry assay to profile IgA1 hinge O-glycoforms and define signatures of disease activity and renal involvement. Methods IgA was affinity-purified from 5 uL of plasma from 91 children (27 with acute IgAV, 26 in remission, and 38 age-matched healthy controls; 24 with and 29 without nephritis), trypsin-digested, and hinge-region O-glycopeptides were quantified by LC-MS. Sixty-nine glycoforms were normalized to a total-IgA1 tryptic peptide. Duplicate measurements showed good analytical repeatability, with a median coefficient of variation of 6%. Groups were compared using Mann-Whitney and Kruskal-Wallis tests (Benjamini-Hochberg FDR). Discrimination was assessed by ROC analysis and cross-validated logistic regression panels. Results Acute IgAV showed broad remodeling of the hinge glycoform profile (35 glycoforms differed with excellent discrimination (AUC 0.93-0.95) for the best ones), with an increase in low-sialylated, agalactosylated species and a decrease in complex sialylated species. The profile was normalized in remission (no glycoform differed from the controls). Two distinct renal patterns emerged: disease-associated glycoforms already altered without nephritis and renal-specific glycoforms altered only in nephritis (H2N2S1, H3N3S5, H3N4S4, and H4N4S3). A four-marker panel discriminated nephritis among IgAV children with a cross-validated AUC of 0.86 (IC95 % 0.75-0.94). Conclusions A single mass-spectrometry assay, from a small blood volume, captures an IgAV-associated IgA1 hinge O-glycoform signature that normalizes in remission, together with a distinct renal involvement associated signature. These findings identify candidate IgA1 O-glycoform signatures associated with IgAV activity and documented renal involvement. Prospective longitudinal studies are required to determine whether the renal-associated panel can predict subsequent nephritis.

Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a genetically heterogeneous group of diseases that regularly lead to kidney failure in mid adulthood. In ADTKD-MUC1 a distinct neoprotein generated by a frameshift mutation, MUC1-fs, is pathogenic and accumulates in distal renal tubular cells. However, the pathomechanism of the disease and the regulation of the MUC1-fs are poorly understood. Primary tubular cells from the urine of several probands were established and immortalized. The length of the repeat region of both alleles of MUC1, as well as the mutated repeat localization were precisely defined by long range sequencing. The pathogenic MUC1-fs is readily detectable in patient-derived cells and has a considerably longer half-life than the wild-type mucin 1. Targeting the secretory pathway with BRD4780, a compound previously reported as putatively therapeutic, leads to downregulation of MUC1-fs in each of our patient-derived cell model. However, wild-type mucin 1 and numerous other transcriptional pathways were also affected by BRD4780, thus being rather unselective. Tubular cells derived from the urine appear to be a suitable model to analyze the pathogenic MUC1-fs of an individual patient, enabling pharmacological studies of novel therapies.

Background Pre-implantation biopsy utility for deceased-donor kidney acceptance is controversial due to processing limitations and interpretive variability. We evaluated whether systematic histological assessment, including expert evaluation and quantification with the BanffNET automated deep learning system (17 lesions), predicts post-transplant failure under optimal laboratory conditions. Methods Biopsies from deceased donor kidneys (N=733) underwent optimized laboratory processing, whole slide imaging, expert Banff 2024 pathologic assessment, and BanffNET lesion quantification. We assessed their incremental predictive value beyond clinical characteristics for early graft dysfunction, longitudinal eGFR/UPCR trajectories, need for indication biopsies, and death-censored graft failure. Results Histopathology improved clinical model discrimination by 1-4% and increased explained variance for longitudinal trajectories by 1-2%. Continuous bivariate surface analysis, however, revealed that while histology adds marginal overall predictive accuracy, mapping continuous composite and individual BanffNET scores against the Kidney Donor Risk Index (KDRI) uncovers distinct topological risk gradients for early graft dysfunction and long-term graft failure. Conclusion While pre-implantation biopsies add minimal overall prognostic value, continuous bivariate mapping of KDRI and BanffNET scores uncovers distinct synergistic risk gradients for graft failure. These continuous clinical-histological surfaces could optimize organ salvage by precisely identifying viable high-KDRI kidneys lacking critical compounded damage and vice versa.

Introduction: Autosomal-dominant tubulointerstitial kidney disease (ADTKD) is characterized by chronic kidney disease (CKD) with an average age of end-stage renal disease (ESRD) of approximately 45 years, bland urinary sediment, the absence of proteinuria and autosomal dominant inheritance. While several causative genes have been found, there remain families in whom no molecular diagnosis has been identified (ADTKD-NMD). Methods: We identified BICC1 truncating variants in several families with ADTKD-NMD in the Wake Forest Rare Inherited Kidney Disease Registry and then screened families in our database and other referred families for BICC1 truncating variants. We performed segregation analysis and characterized affected individuals for clinical and histopathologic phenotypes. We analyzed oligomer formation of BICC1 mutants with wild-type BICC1-, ANKS3- and ANKS6 proteins through co-immunoprecipitation and Western blotting, and we tested for posttranscriptional regulation of the BICC1 target mRNA, Dand5, in a Luciferase reporter assay. Results: We found 6 heterozygous truncating mutations in BICC1 segregating with the ADTKD phenotype in 8 independent pedigrees worldwide. Affected individuals developed kidney failure in the 6th to 7th decade of life that was characterized pathologically by tubular atrophy and interstitial fibrosis. The truncated gene products localized to cytoplasmic bodies and demonstrated various degrees of self-association or binding to the known interaction partners, ANKS3 and ANKS6. While the wild-type BICC1 gene product acts as a posttranscriptional repressor of target mRNAs, all truncation variants exhibited increased expression of substrate mRNA. Conclusions: Truncating variants in BICC1 are a novel cause of ADTKD, segregating with the disease phenotype and upregulating BICC1 target gene expression through a dominant-negative- or a gain-of-function mode of action.

Abstract Endothelial cell (EC) injury is central to the pathogenesis of various renal disorders, highlighting the critical importance of vascular repair for restoring organ health. However, due to limited access to human tissue during active regeneration, the exact reparative processes remain largely unknown. This study aimed to investigate regeneration mechanisms specifically within the glomerular microvasculature by utilizing a selective endothelial cell injury (ECI) model in mice.Lineage tracing identified the origin of regenerating ECs. To uncover the transcriptional dynamics driving these reparative changes, we combined single-cell RNA sequencing and Xenium spatial transcriptomics (ST), mapping distinct glomerular EC (gEC) subpopulations across different phases of injury and recovery. Apold1 emerged as a key regulatory candidate within this process. To functionally validate this gene's specific role during the regenerative phase, Apold1-deficient (Apold1-/-) mice underwent the ECI model. After showing that gECs regenerate primarily from local, pre-existing renal ECs, our transcriptomic analysis identified 10 distinct gEC subpopulations and revealed a complex temporal pattern of regeneration. This process begins with the expression of genes associated with inflammation, followed sequentially by endothelial cell (EC) migration, the activation of immediate early genes, vascular remodeling and cellular proliferation. Within this dynamic process, the EC-specific gene Apold1 was identified as a key regulatory candidate. Apold1-/- mice exhibited impaired endothelial regeneration, characterized by increased endothelial activation and greater immune cell infiltration seven days post-ECI. To our knowledge, this is the first study to elucidate the spatiotemporal mechanisms of glomerular endothelial cell regeneration. By identifying local gECs as the primary source of repair, and stablishing the change in their expression pattern during regeneration, as well as identifying Apold1 as an intrinsic regulator, we have laid the groundwork for future research on renal microvascular disorders.

BackgroundLupus nephritis remains a major cause of chronic kidney disease and kidney failure in systemic lupus erythematosus. Glucocorticoids are central to treatment but are limited by systemic toxicity. We evaluated whether a previously characterized collagen IV 3-targeted liposomal nanoparticle formulation carrying low-dose prednisolone could attenuate established lupus nephritis in MRL/lpr mice. MethodsFemale MRL/lpr mice with disease present at treatment initiation and C57BL/6J control mice received saline or collagen IV 3-targeted prednisolone-loaded nanoparticles (Col4-3-Pred-NPs). Renal outcomes were assessed by longitudinal proteinuria, glomerular filtration rate (GFR), survival, kidney histopathology, renal IgG and C3d deposition, dUTP/TUNEL-associated injury staining, and renal cytokine/chemokine profiling. Body weight, food and water intake, and blood glucose were monitored as measures of general condition and preliminary tolerability. ResultsCol4-3-Pred-NPs improved survival in MRL/lpr mice, reduced cumulative proteinuria burden, and attenuated terminal GFR decline compared with saline-treated MRL/lpr controls. Treatment reduced glomerular and tubulointerstitial injury, lowered composite EGTI histopathology scores, decreased terminal kidney enlargement, reduced glomerular IgG deposition and renal dUTP-positive injury signals, and reduced renal signals for IL-28A/B, IL-7, PD-ECGF, IL-11, CCL6/C10, and IL-15. C3d deposition was not significantly altered. Nanoparticle treatment was not associated with sustained treatment-related increases in blood glucose or body-weight loss during the measured study period. ConclusionsCollagen IV 3-targeted liposomal delivery of low-dose prednisolone attenuated established lupus nephritis in MRL/lpr mice and improved renal structural, functional, inflammatory, and survival outcomes. These findings support further evaluation of glomerulus-targeted nanotherapy as a potential strategy to improve the precision and therapeutic index of glucocorticoid treatment in lupus nephritis.

Introduction: B cell depletion with rituximab leads to complete or partial remission (CR/PR) in only ~60% of patients with primary membranous nephropathy (PMN). Adding belimumab to rituximab may result in greater depletion of memory B cells, limit the re-emergence of autoreactive B cells, and improve clinical responses. Methods: REBOOT Part A (NCT03949855) is a single arm, open-label, pharmacokinetic study where all participants had proteinuria [&ge;] 4g/day and detectable serum anti-phospholipase A2 receptor (anti-PLA2R) antibodies. Participants received belimumab 200 mg subcutaneously weekly for 52 weeks and rituximab 1000 mg intravenously at weeks 4 and 6. Assessments included belimumab exposure at week 4 and CR/PR at week 104. Results: Seventeen participants started belimumab. Belimumab exposure was not significantly reduced in those with high (> 9 g/day) proteinuria at week 4. Among all treated participants, 59% (10/17) achieved CR/PR at week 104, while in per protocol analyses, 91% (10/11) achieved CR/PR at week 104. All participants in per protocol analyses had normal serum albumin and undetectable serum anti-PLA2R by week 104. Circulating memory B cells increased before rituximab and were depleted by rituximab. B cell re-constitution occurred after week 52 with primarily naive and transitional B cells. Belimumab with rituximab was well-tolerated, with one participant discontinuing belimumab due to infection. Conclusion: In this study, a high proportion of participants receiving belimumab with rituximab achieved CR/PR. Thus, a multi-targeted approach to B cell depletion may improve immunologic and clinical outcomes in PMN and is being studied in a larger, randomized, placebo-controlled clinical trial.

Kidney disease affects over 850 million people and leads to degradation of the kidney cortical compartments and kidney failure. Interstitial fibrosis and tubular atrophy (IFTA) is a universal feature of chronic kidney disease, yet the sequence of tubulointerstitial matrix protein (matrisome) changes that underlie the development and progression of IFTA are not fully understood. In particular, post-translational modifications which may stabilize key matrisome components and result in irreversible and functionally detrimental interstitial fibrosis or tubular basement membrane thickening, have yet to be characterized. Post-translational modifications (e.g., acetylation) have been shown to contribute to kidney diseases, yet they have not been investigated in chronic kidney disease progression. Herein, we established feasibility of matrisome protein quantification in the tubulointerstitium, with concurrent matrisome protein post-translational modification quantification, in archived diagnostic human kidney biopsies, using laser capture microdissection, liquid chromatography tandem mass spectrometry (LC-MS/MS), and bioinformatics analysis. In this pilot study, we focused on two conditions associated with IFTA progression: diabetic nephropathy and kidney transplantation. We examined both healthy and chronically damaged tubulointerstitium in two human kidney biopsies, one representing each condition. We identified signature protein markers of tubulointerstitium (e.g., UMOD, SLC12A1) in abundance, confirming sample composition, and observed uniformity in protein abundance across replicates from the same biopsies. We found increases in certain collagen isoforms (COL1A1, COL6A3) and other ancillary proteins in areas of IFTA. We also successfully quantified post-translational modifications, confirming that hydroxylproline was the most abundant modification in healthy tubulointerstitium from the kidney transplant biopsy, and that hydroxyllysine was also highly abundant and could be confidently quantitated on two collagen isoforms (COL1A1, COL4A2). Lastly, we performed power analysis to determine the required sample size to achieve significant power and false discovery rate. Several proteins exhibited large Hedge effect sizes in the tubulointerstitium (ANPEP, PRODH2), indicating their potential usefulness as fibrosis signatures. Our study is a first step toward comprehensive characterization of tubulointerstitial matrisome changes, including post-translational modifications seen with IFTA progression. Subsequent studies will potentially reveal new molecular markers of key early events in chronic kidney disease progression, and new therapeutic targets for mitigating this process. Data are available via ProteomeXchange identifier PXD079025.

INTRODUCTION RNA editing has been implicated in endogenous double-stranded RNA (dsRNA) sensing and inflammatory disease, but its prevalence, genetic regulation, and consequences in diseased human kidney tissue have not been systematically characterized. Because ADAR enzymes edit multiple neighboring adenosines often in the same transcript, analyzing these sites holistically (as "clusters") may reveal effects missed by single-site analysis. METHODS We profiled both single-site and cluster A-to-I RNA editing in the kidneys of 215 participants from the Nephrotic Syndrome Study Network with focal segmental glomerulosclerosis or minimal change disease who had microdissected glomerular and/or tubulointerstitial RNA-seq and blood genome sequencing. We tested single-site and cluster editing association with estimated glomerular filtration rate, proteinuria, and an interferon stimulated gene expression score. To discover the genetic determinants of editing, we conducted mapping of both single-site, cis-editing QTL and cluster-level editing QTLs (cledQTLs). We then tested cledQTLs for colocalization with kidney eQTLs and kidney-relevant GWAS. RESULTS Greater cluster mean editing in tubulointerstitium was associated with lower interferon-stimulated gene activity (P = 4.81 x 10-9), lower UPCR (P = 0.01) and higher eGFR (P = 8.52 x 10-5). Genetic mapping identified 290 glomerular and 473 tubulointerstitial single-site edQTLs, as well as 21 glomerular and 51 tubulointerstitial cledQTLs. We identified 10 colocalized signals between cledQTL and GWAS and 14 between cledQTL and eQTL. Nine of 51 tubulointerstitial cledQTL clusters were individually associated with eGFR in NEPTUNE. CONCLUSION These results identify A-to-I RNA editing as a measurable and partly genetically regulated molecular phenotype in proteinuric kidney disease and nominate clustered editing of tubulointerstitial transcripts as a putative contributor to attenuated immune activity and higher kidney function. Cluster-level analysis identified additional genetically regulated editing patterns and colocalized signals not detected at individual sites, highlighting the added value of analyzing nearby editing sites as clusters.

Introduction: C3 glomerulopathy (C3G) is driven by fluid-phase alternative complement pathway dysregulation, with emerging evidence linking glomerular neutrophil infiltration to disease severity. Neutrophil extracellular traps (NETs) are implicated in other forms of glomerulonephritis. However, their participation in the pathogenesis of C3G remains undefined. Methods: Kidney biopsies from 33 patients with C3G (15 with dense deposit disease [DDD] and 18 with C3 glomerulonephritis [C3GN]) were compared with 15 anti-neutrophil cytoplasmic antibody associated vasculitis (AAV) biopsies as a neutrophil-rich disease control in this retrospective cross-sectional study. Glomerular neutrophils and NETs were identified using immunofluorescence, staining for myeloperoxidase, citrullinated histone H3, peptidyl arginine deiminase-4, and DNA. Supervised machine learning was used to quantify glomerular NET formation, and the data were correlated with kidney function at time of biopsy using linear regression. Results: Intraglomerular NETs were abundant and detected in the majority of glomeruli in C3G biopsies. Compared with AAV, C3G showed a significantly higher fraction of neutrophils forming NETs, despite similar neutrophil counts per glomerulus. NET abundance was similar in DDD and C3GN. In exploratory analyses, a greater proportion of glomeruli containing NETs was associated with lower kidney function (estimated glomerular filtration rate) at biopsy, and this association remained significant after adjustment for age, C3G subtype, and interstitial fibrosis. Conclusions: These observations demonstrate that intraglomerular NETs are a common and prominent observation in C3G and are associated with reduced kidney function at biopsy. These findings raise the possibility that NET deposition in glomeruli is a previously unrecognized driver of glomerular injury in C3G.

BackgroundTraditional immunohistochemistry (IHC) with chromogen detection has limited multiplex capacity, detecting at most 4 protein markers per tissue section simultaneously, thereby restricting comprehensive spatial analysis of valuable human biopsies. We developed and validated a robust serial IHC (sIHC) staining method to detect multiple antigens on a single kidney biopsy slide, maximizing data yield for diagnosing and studying complex kidney diseases. MethodsFormalin-fixed, paraffin-embedded kidney biopsy sections were subjected to repeated IHC/imaging cycles with antibody removal using an optimized sodium dodecyl sulfate-glycerol buffer stripping protocol. Images were then co-registered, and analysis was performed using a variety of methodologies, including color deconvolution, cell segmentation, and spatial clustering. ResultsThis optimized sIHC method successfully detected up to 20 antigens on a single slide. Combining image analysis and artificial intelligence software, for example with HALO (Indica Labs), the assay assembles high-dimensional images and enables quantitative histology and single-cell spatial analysis. Using this advanced method, we were able to identify rare cell populations, such as double-negative T cells, that are challenging to detect conventionally. ConclusionWe have developed a validated, high-capacity sIHC protocol that uses standard IHC procedures with commercially available, clinically validated off-the-shelf antibodies. This method is a valuable, cost-effective tool for obtaining extensive, high-dimensional single-cell-resolved spatial data from limited pathology samples, such as a human kidney biopsy.

Kidney transplant recipients experience a higher burden of several malignancies, yet the factors associated with prostate cancer presentation after transplantation remain poorly understood. Unlike malignancies strongly associated with impaired immune surveillance, prostate cancer has not consistently demonstrated an increased incidence after transplantation, suggesting that different mechanisms may underlie disease presentation. This study evaluated recipient, donor, transplant, immunologic, and immunosuppressive factors associated with prostate cancer phenotype after kidney transplantation. A retrospective cohort study was conducted using national transplant registry data from adult kidney transplant recipients diagnosed with post-transplant prostate cancer between 2015 and 2024. Cases were classified as de novo (no pre-transplant history of prostate cancer) or recurrent (documented pre-transplant history). Multivariable Firth penalized logistic regression was used to evaluate factors associated with recurrent phenotype. Prespecified sensitivity analyses included deceased donor restricted models, incorporation of donor organ quality variables, and adjustment for time from transplantation to cancer diagnosis. Exploratory machine learning analyses included elastic net logistic regression, random forest, and extreme gradient boosting. The cohort included 660 recipients, of whom 623 (94.4%) had de novo disease and 37 (5.6%) had recurrent disease. Recipient age was the only variable consistently associated with recurrent phenotype across primary and sensitivity analyses (adjusted odds ratio per year 1.11, 95% CI 1.05-1.17; p<0.001). Immunosuppressive regimen, donor characteristics, immunologic variables, and time from transplantation to cancer diagnosis were not independently associated with phenotype in the primary cohort. In deceased donor restricted analyses, alemtuzumab induction showed an exploratory association with recurrent phenotype, although estimates were imprecise. Machine learning models demonstrated modest discrimination and calibration and did not outperform penalized regression approaches. These findings suggest that, among kidney transplant recipients with prostate cancer, differences between recurrent and de novo presentation are more closely associated with recipient age and underlying disease characteristics than with transplant exposures or specific immunosuppressive regimens.

The kidney is a highly energetic organ, requiring substantial ATP production through mitochondrial oxidative phosphorylation to support tubular reabsorption. Metabolic reprogramming and impaired mitochondrial function are implicated in diabetic kidney disease, yet direct assessment of mitochondrial respiratory flux in the human kidney has been constrained by limited access to freshly obtained tissue. Consequently, much of the evidence supporting altered renal mitochondrial function in diabetes derives from animal models that do not fully recapitulate the human condition. We established a workflow for real-time bioenergetic profiling of fresh kidney cortex obtained during nephrectomy from living individuals with diabetes and preserved kidney function. Mitochondrial respiration, electron transport system activity and tubular mitochondrial morphology were compared with age- and sex-matched, histopathologically normal non-diabetic controls. High-resolution respirometry revealed increased mitochondrial respiratory flux in permeabilised diabetic kidney cortex. In contrast, mitochondria isolated from the same tissue exhibited reduced respiratory capacity and impaired complex I activity. Quantitative analysis of tubular cells demonstrated increased mitochondrial volume density together with greater mitochondrial fragmentation in diabetes. These findings reveal that the human kidney undergoes substantial metabolic adaptation early in diabetes, before measurable loss of kidney function. Increased tissue-level respiratory flux despite intrinsic mitochondrial impairment suggests that expansion and remodelling of the mitochondrial network may initially compensate for reduced organelle efficiency and sustain the kidneys high energetic demands. This compensatory state may, however, increase metabolic stress and vulnerability to subsequent kidney injury. To our knowledge, this study provides the first direct tissue-level functional evidence that mitochondrial metabolism is reprogrammed in the human kidney in diabetes before measurable kidney dysfunction develops. It defines an early bioenergetic signature characterised by tissue hypermetabolism despite impaired mitochondria-specific respiratory capacity, challenging the concept that diabetes produces a uniform decline in renal mitochondrial function. Failure to sustain this adaptive state may represent a critical transition towards diabetic kidney disease. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/740003v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@1a147a2org.highwire.dtl.DTLVardef@16614e8org.highwire.dtl.DTLVardef@e6c895org.highwire.dtl.DTLVardef@17ad6ab_HPS_FORMAT_FIGEXP M_FIG C_FIG One Sentence SummaryDiabetes drives early metabolic reprogramming of the human kidney before measurable kidney dysfunction

Renal ischemia reperfusion injury (IRI) is a major driver of acute kidney injury and a critical determinant of long term renal outcomes. Although sex differences in susceptibility to renal injury are well recognized, the hormonal mechanisms underlying these disparities remain incompletely understood. Prolactin (PRL), a pleiotropic hormone, has been implicated in both protective and deleterious renal effects, while Cathepsin D (CTD), a lysosomal protease, cleaves PRL into Vasoinhibins that possess antiangiogenic and immunomodulatory properties. The impact of CTD deficiency on PRL's role in renal IRI has not been defined. Here, we investigated whether CTD regulated prolactin signaling modulates renal responses to IRI in a sex dependent manner. Wild type (WT) and heterozygous CTD mice of both sexes were subjected to unilateral renal IRI. PRL overexpression was achieved via lentiviral vector, and renal function, inflammatory cytokines, and angiogenic factors were assessed. In vitro Prolactin cleavage assays confirmed the enzymatic role of CTD. Proteomic analysis of renal cortex tissue was performed using label free LC MS/MS and pathway enrichment tools. CTD cleaved PRL into Vasoinhibins at physiological pH, an effect blocked by Pepstatin A. PRL effects varied by sex and genotype. In WT females, PRL reduced renal dysfunction and increased IL-6 and TGF beta; expression following IRI. CTD+/- females exhibited protection from injury, with PRL treatment reversing IL-6 induction. In males, PRL alone had modest effects, but CTD deficiency led to pronounced creatinine elevation, which PRL treatment normalized. Proteomic data revealed differential regulation of cytoskeletal and inflammatory proteins. Cathepsin D heterozygosity modifies PRL's biological effects on the injured kidney. The CTD, PRL axis regulates key inflammatory and angiogenic responses after IRI, revealing new mechanistic insights and potential therapeutic targets in acute kidney injury.

Biological sex is an important determinant of kidney disease susceptibility and outcomes. The epigenetic modifier KDM6A is an X chromosome-expressed lysine demethylase and molecular scaffold that escapes X chromosome inactivation. Here, we compared the effects of deletion of KDM6A from kidney tubule epithelial cells in female and male mice (KDM6ATubKO). Knockout of KDM6A from tubule cells aggravated kidney fibrosis caused by unilateral ureteral obstruction (UUO) in female mice, whereas male mice were unaffected by KDM6A absence. Unexpectedly, female (but not male) KDM6ATubKO mice developed spontaneous glucosuria that, when stressed by ligation of one ureter, presented as polyuria and a Fanconi renotubular syndrome-like picture affecting the unobstructed kidney. Absence of KDM6A from tubule epithelial cells of female mice caused mitochondrial circularization, tubule cell vacuolization with focal atrophy and lymphoid infiltration, and diminished sodium/glucose cotransporter 2 (SGLT2). Spatial transcriptomics and untargeted metabolomics revealed that knockout of KDM6A in female mice caused a shift in gene programs and metabolic pathways indicative of tubule cell metabolic dysfunction. In male mice, transcripts of the Y chromosome-expressed gametolog of Kdm6a, Uty were present in tubule epithelial cells at levels comparable to Kdm6a and they were upregulated with UUO. In summary, KDM6A is essential for normal tubule epithelial cell homeostasis in females but not in males. KDM6A and UTY are a dynamically regulated X-Y gene pair with at least partial compensatory overlap in function necessary for the preservation of kidney health and stress tolerance. Graphical abstract. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=145 SRC="FIGDIR/small/740137v1_ufig1.gif" ALT="Figure 1000"> View larger version (29K): org.highwire.dtl.DTLVardef@7d26a4org.highwire.dtl.DTLVardef@740972org.highwire.dtl.DTLVardef@1851f7org.highwire.dtl.DTLVardef@ad6485_HPS_FORMAT_FIGEXP M_FIG C_FIG

APOL1 risk variants are the strongest genetic determinants of HIV-associated nephropathy (HIVAN), yet the mechanisms linking inflammation to APOL1-mediated podocyte injury remain poorly understood because authentic patient-derived human disease models are lacking. Using urine-derived podocytes established from children with HIVAN and endogenous APOL1 reporter cell lines derived from these cells, we identified a previously unrecognized pathway of inflammatory, cathepsin-dependent APOL1 proteolysis. Endogenous APOL1 cleavage was detected in patient-derived podocytes, whereas reporter cell lines enabled the identification and functional characterization of N-terminal and C-terminal APOL1 fragments with distinct intracellular localization and pathogenic functions. The nuclear N-terminal fragment activated inflammatory transcriptional programs and promoted podocyte injury, whereas the membrane-associated C-terminal fragment mediated membrane toxicity and remained susceptible to pharmacologic inhibition by inaxaplin. Cathepsin S directly cleaved APOL1 in vitro, linking inflammatory signaling to APOL1 fragmentation. These findings identify inflammatory APOL1 proteolysis as a mechanism that partitions APOL1 toxicity into distinct pathogenic programs and nominate APOL1 processing as a therapeutic target for HIV-associated and other APOL1-mediated kidney diseases.

Intracranial aneurysms (IA) and their rupture (subarachnoid haemorrhage, SAH) are a rare but serious complication of autosomal dominant polycystic kidney disease (ADPKD). Both genetic and environmental risk factors contribute to the pathogenesis of IA and SAH, but specific information on risk factors in the ADPKD population are limited and international clinical guidelines mainly recommend screening for ADPKD patients with a family history of IA or SAH. We assessed the associations of monogenic variants, polygenic risk, and clinical factors with the diagnosis of IA or SAH in 2,200 adult ADPKD patients from three cohorts: the Irish Kidney Gene Project (IKGP, n=475), FinnGen (n=826), and Genomics England (GEL, n=899). Polygenic risk scores (PRS) for IA, hypertension, and smoking intensity were derived from previously published GWAS summary statistics and additionally conditioned using mtCOJO to account for their genetic correlation. IA or SAH was diagnosed in 158 of 2,200 patients (7.2%; mean age at diagnosis 51.1 years). Female sex (HR 2.21, 95% CI 1.50-3.25, p=6.52x10^-5) and smoking (HR 2.06, 95% CI 1.43-2.96, p=9.49x10^-5) were associated with IA or SAH in univariate Cox proportional hazards models, while diabetes was protective (HR 0.39, 95% CI 0.22-0.70, p=1.37x10^-3). Monogenic variant status was not found to associate with increased risk of IA or SAH. Polygenic score for IA was associated with increased risk of IA or SAH, with a 1 standard deviation increase in PRS associated with a pooled hazard ratio (HR) of 1.30 (95% CI 1.09-1.57, p=4.66x10^-3), and the association of the conditioned IA PRS remained in multivariate Cox proportional hazards models accounting for clinical factors and monogenic variants (HR 1.26, 95% CI 1.03-1.55, p=0.02). The addition of polygenic scores added significant prognostic information for IA or SAH beyond clinical risk factors in FinnGen (p=3.61x10^-3) and GEL (p=8.84x10^-3) but not in IKGP, as assessed by the likelihood ratio test. Overall, our study shows that the strongest risk factors for IA or SAH in ADPKD patients are smoking history, female sex, and polygenic risk for IA. Hypertension was not associated with IA (HR 0.50, 95% CI 0.24-1.00, p=0.051), likely due to the high prevalence of hypertension in this population across cohorts (69.6-85.3%). While family history may be considered a proxy of genetic risk, this study suggests that family history itself may be of limited utility in discriminating individuals with ADPKD at risk of IA or SAH. Keywords: Intracranial Aneurysms, subarachnoid haemorrhage, Autosomal Dominant Polycystic Kidney Disease, Polygenic Risk Scores, Hypertension, Family History

While ultra-rare missense variants in UMOD cause highly penetrant autosomal dominant tubulointerstitial kidney disease, a more frequent UMOD T62P variant conveys intermediate risk with variable penetrance. To determine whether age or polygenic risk contributes to the variable penetrance of T62P, we combined genotype and phenotype data from 882,306 individuals across the UK Biobank (discovery cohort) and the All of Us and MyCode biobanks (validation cohorts). We also analyzed the impact of aging on uromodulin processing and cellular stress in stably transfected kidney tubular cells expressing wild-type or mutant UMOD. We compared the effects of the GPS on risk of CKD between T62P carriers and non-carriers and tested for the GPS-by-T62P interaction. The UMOD T62P variant was reproducibly associated with increased risk of CKD in an age-dependent manner. Compared to wild-type, clones of T62P-expressing cells exhibited a defective uromodulin maturation profile, causing endoplasmic reticulum retention and stress. We also observed significant T62P-by-GPS interaction, with T62P carriers in the top quintile of the GPS having over 5-fold higher risk of CKD compared to population average (OR 5.17, 95%CI: 2.94-9.08, P=1.0E-08). In summary, we demonstrate that the penetrance of kidney disease in T62P carriers is strongly modified by both age and polygenic risk.